Progesterone receptor is involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin-stimulated breast cancer cells proliferation

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 223-231

  Chen, Yun Ju ^a   Hung, Chao Ming ^b   Kay, Nari ^b   Chen, Chin Chen ^b   Kao, Ying Hsien ^a   Yuan, Shyng Shiou ^a,b  

^a I SHOU UNIVERSITY   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

Author keywords

Akt FoxO3a; PR; Proliferation; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CDC2 PROTEIN; CDC25C PROTEIN; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOGENS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TETRACHLORODIBENZODIOXIN;

EID: 84862832587     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.017     Document Type: Article

References (53)

1. Birnbaumm L.S., Fenton S.E. Cancer and developmental exposure to endocrine disruptors. Environ. Health Perspect. 2003, 111:389-394.
2. Brody J.G., Moysich K.B., Humblet K.R., Attfield K.R., Beehler G.P., Rudel R.A. Environmental pollutants and breast cancer. Cancer 2007, 109:2667-2711.
3. Rayner J.L., Enochm R.R., Fenton S.E. Adverse effects of prenatal exposure to atrazine during a critical period of mammary gland growth. Toxicol. Sci. 2005, 87:255-266.
4. Rudel R.A., Attfield K.R., Schifano J.N., Brody J.G. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer 2007, 109:2635-2666.
5. Hardell L., Lindström G., Liljegren G., Dahl P., Magnuson A. Increased concentrations of octachlorodibenzo-p-dioxin in cases with breast cancer - results from a case-control study. Eur. J. Cancer Prev. 1996, 5(5):351-357.
6. Warner M., Eskenazi B., Mocarelli P., Gerthoux P.M., Samuels S., Needham L., Patterson D., Brambilla P. Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ. Health Perspect. 2002, 110(7):625-628.
7. Polychlorinated Dibenzo-para-dioxins and Polychlorinated Dibenzofurans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1997, vol. 69. International Agency for Research on Cancer, Lyon.
8. Kogevinas M. Human health effects of dioxins: cancer reproductive and endocrine system effects. Hum. Reprod. Update 2001, 7:331-339.
9. Fernandez-Salguero P.M., Hilbert D.M., Rudikoff S., Ward J.M., Gonzalez F.J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8,-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 1996, 140:173-179.
10. Beischlag T.V., Luis Morales J., Hollingshead B.D., Perdew G.H. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 2008, 18(3):207-250.
11. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 1993, 15(1):17-35.
12. Zhao X.J., Huang Y.H., Yu Y.C., Xin X.Y. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol. Oncol. 2010, 118(1):69-75.
13. Graham J.D., Yager M.L., Hill H.D., Byth K., O'Neill G.M., Clarke C.L. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol. Endocrinol. 2005, 19(11):2713-2735.
14. Medina D. Mammary developmental fate and breast cancer risk. Endocr. Relat. Cancer 2005, 12(3):483-495.
15. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001, 344(4):276-285.
16. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 2001, 8(2):269-280.
17. Boonyaratanakornkit V., Edwards D.P. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin. Reprod. Med. 2007, 25(3):139-153.
18. Matsumura F. How important is the protein phosphorylation pathway in the toxic expression of dioxin-type chemicals?. Biochem. Pharmacol. 1994, 48:215-224.
19. North C.M., Crawford R.B., Lu H., Kaminski N.E. 2,3,7,8-Tetracholorodibenzo-p-dioxin-mediated suppression of Toll-like receptor stimulated B lymphocyte activation and initiation of plasmacytic differentiation. Toxicol. Sci. 2010, 116:99-112.
20. Nishiumi S., Yoshida M., Azuma T., Yoshida K., Ashida H. 2,3,7,8-Tetracholorodibenzo-p-dioxin impaires an insulin signaling pathway through the induction of tumor necrosis factor-alpha in adipocytes. Toxicol. Sci. 2010, 115:482-491.
21. Park S.J., Yoon W.K., Kim H.J., Son H.Y., Cho S.W., Jeong K.S., Kim T.H., Kim S.H., Kim S.R., Ryu S.Y. 2,3,7,8-Tetracholorodibenzo-p-dioxin activates ERK and p38 mitogen-activated protein kinases in RAW 264.7 cells. Anticancer Res. 2005, 25:2831-2836.
22. Dong B., Matsumura F. The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells. Mol. Endocrinol. 2009, 23(4):549-558.
23. Ballaré C., Uhrig M., Bechtold T., Sancho E., Di Domenico M., Migliaccio A., Auricchio F., Beato M. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol. Cell. Biol. 2003, 23(6):1994-2008.
24. Dressing G.E., Hagan C.R., Knutson T.P., Daniel A.R., Lange C.A. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr. Relat. Cancer 2009, 16:351-361.
25. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17(7):2008-2018.
26. Saitoh M., Ohmichi M., Takahashi K., Kawagoe J., Ohta T., Doshida M., Takahashi T., Igarashi H., Mori-Abe A., Du B., Tsutsumi S., Kurachi H. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 2005, 146(11):4917-4925.
27. Subtil-Rodríguez A., Millán-Ariño L., Quiles I., Ballaré C., Beato M., Jordan A. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol. Cell. Biol. 2008, 28(11):3830-3849.
28. Yamamoto T., Matsumoto K., Kurachi H., Okamoto Y., Nishio Y., Sakata M., Tasaka K., Murata Y. Progesterone inhibits transcriptional activation of human chorionic gonadotropin-alpha gene through protein kinase A pathway in trophoblast cells. Mol. Cell. Endocrinol. 2001, 182(2):215-224.
29. Law M.L., Kao F.T., Wei Q., Hartz J.A., Greene G.L., Zarucki-Schulz T., Conneely O.M., Jones C., Puck T.T., O'Malley B.W. The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc. Natl. Acad. Sci. USA 1987, 84(9):2877-2881.
30. Baulieu E.E. A novel approach to human fertility control: contragestion by the anti-progesterone RU 486. Eur. J. Obstet. Gynecol. Reprod. Biol. 1988, 28(2):125-129.
31. Zaytseva T.S., Goncharova V.N., Morozova M.S., Astakhova T.M., Manuilova I.A., Pankov Y.A. The effect of RU486 on progesterone and oestrogen receptor concentration in human decidua on early pregnancy. Hum. Reprod. 1993, 8(8):1288-1292.
32. Bjorklund M., Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 2005, 1755(1):37-69.
33. Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views. J. Pathol. 2008, 214(3):283-293.
34. Overall C.M., Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6(3):227-239.
35. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13(8):781-792.
36. Jin P., Hardy S., Morgan D.O. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J. Cell Biol. 1998, 141(4):875-885.
37. Perdiguero E., Nebreda A.R. Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 2004, 3(6):733-737.
38. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9(6):400-414.
39. Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., Lau K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010, 17(9):1511-1523.
40. Brazil D.P., Park J., Hemmings B.A. PKB binding proteins. Getting in on the Akt. Cell 2002, 111(3):293-303.
41. Carnero A. The PKB/AKT pathway in cancer. Curr. Pharm. Des. 2010, 16(1):34-44.
42. Gross D.N., Wan M., Birnbaum M.J. The role of FOXO in the regulation of metabolism. Curr. Diabets Rep. 2009, 9(3):208-214.
43. Huang H., Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 2007, 120(15):2479-2487.
44. Burgering B.M., Kops G.J. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 2002, 27(7):352-360.
45. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
46. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29(6 Suppl. 16):15-18.
47. Safe S., Wormke M., Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J. Mammary Gland Biol. Neoplasia 2000, 5:295-306.
48. Safe S., Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem. Res. Toxicol. 2003, 16:807-816.
49. Wong P.S., Li W., Vogel C.F., Matsumura F. Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR). BMC Cancer 2009, 9(1):234-249.
50. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2(4):339-345.
51. Puga A., Hoffer A., Zhou S., Bohm J.M., Leikauf G.D., Shertzer H.G. Sustained increase in intracellular free calcium and activation of cyclooxygenase-2 expression in mouse hepatoma cells treated with dioxin. Biochem. Pharmacol. 1997, 54(12):1287-1296.
52. Oikawa K., Ohbayashi T., Mimura J., Iwata R., Kameta A., Evine K., Iwaya K., Fujii-Kuriyama Y., Kuroda M., Mukai K. Dioxin suppresses the checkpoint protein, MAD2, by an aryl hydrocarbon receptor-independent pathway. Cancer Res. 2001, 61(15):5707-5709.
53. Lin T.M., Ko K., Moore R.W., Buchanan D.L., Cooke P.S., Peterson R.E. Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed male mice. J. Toxicol. Environ. Health A 2001, 64(4):327-342.